New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly fivefold to $35.8 ...
1d
MedPage Today on MSNPatients Struggle With Lack of Consistent Coverage for New Weight-Loss DrugsCoverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The Trump administration’s delay of what was supposed to be this week’s regularly scheduled meeting of the CDC’s vaccine ...
3d
24/7 Wall St. on MSNHIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
With Kennedy now in the driver's seat, the industry will likely expect more: It aims to make bolder health claims for its ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results